Ingenza – a world-leading protein CRDMO – has today announced a strategic relationship with Ab Biotechnology – a MHRA‑licensed GMP facilities provider – to support the development and GMP manufacturing of innovative biotechnology products. With the companies being located and…
In this instalment of our Inside Ingenza series, Jack Kay discusses our in-house AI/ML platform, codABLE™, and how it delivers unparalleled predictability and precision when tuning protein expression compared to traditional methods.
A scientist who joined Ingenza as a 16-year-old apprentice has completed a PhD while working full-time at the company – a career path that highlights the long-term impact of work-based learning as part of Scottish Apprenticeship Week. Jack Kay, now…
Ingenza – a world-leading leading engineering biology CRDMO based in Edinburgh, Scotland – has developed GenXpress Bacillus, a powerful orthogonal protein production system. With performance comparable to the best E. coli expression systems, the new technology offers Ingenza customers a highly productive alternative that…
Ingenza Limited, a technology driven contract research, development and manufacturing organisation (CRDMO), recently welcomed Nick Challoner as its new Chief Executive Officer. Nick is a seasoned leader with more than three decades of experience in innovation, strategy and international business…
In this instalment of our Inside Ingenza series, Fraser Brown – Ingenza’s Head of Chemistry and Analytical Development – talks about a particularly complex protein we worked with.
Fermentation plays a vital role in delivering high quality, scalable products for biopharmaceuticals and sustainable chemicals. But success depends on precisely controlling parameters such as temperature, pH, nutrient supply and oxygen levels. Optimising these conditions – and scaling them efficiently…
Deuterium (D) is a heavy stable isotope of hydrogen (H) and is an increasingly utilised strategic modification to improve drug performance (Di Martino, 2023). The substitution of deuterium isotope for hydrogen offers improved pharmacokinetic performance by extending drug half-life against metabolism…
Ingenza Limited, a technology driven contract research, development and manufacturing organisation (CRDMO), has announced the appointment of Nick Challoner as its new Chief Executive Officer, effective the 1st of October, 2025. Nick brings over 30 years of experience in business…
The pharmaceutical landscape is evolving rapidly with the introduction of platform technologies, often enhanced by machine learning (ML), and Ingenza is one of the few contract, research, development and manufacturing organisations (CRDMOs) to embrace this approach. Ingenza’s inGenius® platform plays a pivotal role in accelerating…